Intismeran

also known as mRNA-4157 · V940

Developed for: non-small cell lung carcinoma
Investigated by: Merck Sharp & Dohme LLC · ModernaTX, Inc.

Trials 1

today NCT07513376 · Ph 3

20272028202920302031203220332034

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 3	NCT07513376	May 2026 → Aug 2034 expected	non-small cell lung carcinoma	Merck Sharp & Dohme LLC	Recruiting	No outcome recorded

Press releases naming this drug 28 releases

Date	Issuer	Release
2026-08-19	Merck Sharp & Dohme LLC	Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma merck.com ↗
2026-06-01	Merck Sharp & Dohme LLC	Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA® (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting merck.com ↗
2026-06-01	ModernaTX, Inc.	Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting q4web.com ↗
2026-01-20	Merck Sharp & Dohme LLC	Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA® (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection merck.com ↗
2026-01-20	ModernaTX, Inc.	Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection q4web.com ↗
2024-10-28	Merck Sharp & Dohme LLC	Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC) merck.com ↗
2024-10-28	ModernaTX, Inc.	Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC) q4web.com ↗
2024-06-03	Merck Sharp & Dohme LLC	Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA® (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection merck.com ↗
2024-06-03	ModernaTX, Inc.	Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection q4web.com ↗
2023-12-14	Merck Sharp & Dohme LLC	Moderna and Merck Announce mRNA-4157 (V940) in Combination with KEYTRUDA® (pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA At Three Years merck.com ↗
2023-12-14	ModernaTX, Inc.	Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus Keytruda at Three Years q4web.com ↗
2023-12-11	Merck Sharp & Dohme LLC	Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer merck.com ↗
2023-12-11	ModernaTX, Inc.	Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer q4web.com ↗
2023-07-26	Merck Sharp & Dohme LLC	Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk(Stage IIB-IV) Melanoma merck.com ↗
2023-07-26	ModernaTX, Inc.	Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma q4web.com ↗
2023-06-05	Merck Sharp & Dohme LLC	Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA® (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival (DMFS) in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA merck.com ↗
2023-06-05	ModernaTX, Inc.	Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA q4web.com ↗
2023-05-30	ModernaTX, Inc.	Moderna Announces Phase 2 Data on mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, to be Presented at the 2023 ASCO Annual Meeting q4web.com ↗
2023-04-16	Merck Sharp & Dohme LLC	Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination With KEYTRUDA® (pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA merck.com ↗
2023-04-16	ModernaTX, Inc.	Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection versus KEYTRUDA q4web.com ↗
2023-04-06	Merck Sharp & Dohme LLC	mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA® (pembrolizumab), Receives PRIME Scheme Designation from the European Medicines Agency for Adjuvant Treatment of Patients with High-Risk Stage III/IV Melanoma Following Complete Resection merck.com ↗
2023-04-06	ModernaTX, Inc.	MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection q4web.com ↗
2023-03-14	ModernaTX, Inc.	Moderna Announces Phase 2 Data on mRNA-4157/V940, an Investigational mRNA Personalized Cancer Vaccine, to be Presented at the 2023 AACR Annual Meeting q4web.com ↗
2023-02-22	Merck Sharp & Dohme LLC	Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA® (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Complete Resection merck.com ↗
2023-02-22	ModernaTX, Inc.	Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA(R) (pembrolizumab), was Granted Breakthrough Therapy Designation by the FDA for Adjuvant Treatment of Patients With High-Risk Melanoma Following Complete Resection q4web.com ↗
2022-12-13	Merck Sharp & Dohme LLC	Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination With KEYTRUDA® (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial merck.com ↗
2022-12-13	ModernaTX, Inc.	Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial q4web.com ↗
2017-11-15	ModernaTX, Inc.	Moderna Announces First-in-Human Dosing for Phase 1 Study (KEYNOTE-603) of mRNA-4157, a Personalized Cancer Vaccine, for the Treatment of Solid Tumors modernatx.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Intismeran	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07513376 ↗
Known as	mRNA-4157	“One trial medicine is intismeran (also called V940/mRNA-4157) and the other is subcutaneous pembrolizumab (also called SC pembrolizumab and MK-3475A).” NCT07513376 ↗
Known as	V940	“One trial medicine is intismeran (also called V940/mRNA-4157) and the other is subcutaneous pembrolizumab (also called SC pembrolizumab and MK-3475A).” NCT07513376 ↗
Route	Intramuscular	“Participants will receive intismeran 1 mg via intramuscular (IM) injection” NCT07513376 ↗